Payment overview · 2025
General Payments
$388.00
22 reported records · 15 companies
Healthcare provider profile · identity verified
James Rossi
Allopathic & Osteopathic Physicians|General Practice · LEXINGTON, KY · NPI 1659802924
Verified facts
What the public records show
CMS Open Payments records show James Rossi received $388.00 in general payments during 2025 across 22 reported records.
Lilly USA, LLC accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro, Ozempic, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.09 | 18.1% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $50.02 | 12.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.49 | 10.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.15 | 8.3% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.11 | 6.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.09 | 5.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.67 | 5.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.28 | 4.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.46 | 4.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.50 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.09 | 4.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.73 | 4.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.68 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.01 | 3.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.63 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $375.58 | 21 |
| Education | $12.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.09 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 239 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 141 |
| Lisinopril | Lisinopril | 440 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 128 |
| Losartan Potassium | Losartan Potassium | 368 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 101 |
| Omeprazole | Omeprazole | 266 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 61 |
| Simvastatin | Simvastatin | 189 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 54 |
| Metformin Hcl | Metformin Hcl | 169 | 50 |
| Gabapentin | Gabapentin | 157 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 57 |
| Montelukast Sodium | Montelukast Sodium | 145 | 48 |
| Tramadol Hcl | Tramadol Hcl | 140 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 45 |
| Alprazolam | Alprazolam | 128 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 43 |
| Finasteride | Finasteride | 124 | 39 |
| Allopurinol | Allopurinol | 123 | 38 |
| Meloxicam | Meloxicam | 123 | 44 |
| Trazodone Hcl | Trazodone Hcl | 120 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 40 |
| Metformin Hcl Er | Metformin Hcl | 115 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 46 |
| Carvedilol | Carvedilol | 111 | 35 |
| Famotidine | Famotidine | 110 | 39 |
| Atenolol | Atenolol | 102 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 28 |
| Glipizide Er | Glipizide | 92 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 29 |
| Synthroid | Levothyroxine Sodium | 89 | 24 |
| Furosemide | Furosemide | 88 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 28 |
| Sertraline Hcl | Sertraline Hcl | 86 | 29 |
| Ozempic | Semaglutide | 83 | 16 |
| Bupropion Xl | Bupropion Hcl | 82 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 25 |
| Buspirone Hcl | Buspirone Hcl | 75 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 29 |
| Eliquis | Apixaban | 71 | 25 |
| Diazepam | Diazepam | 69 | 16 |
| Clonazepam | Clonazepam | 68 | 13 |
| Mounjaro | Tirzepatide | 68 | 11 |
| Ezetimibe | Ezetimibe | 67 | 23 |
| Jardiance | Empagliflozin | 66 | 22 |
| Azithromycin | Azithromycin | 65 | 61 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Propranolol Hcl | Propranolol Hcl | 61 | 18 |
| Spironolactone | Spironolactone | 60 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 20 |
| Glimepiride | Glimepiride | 56 | 17 |
| Glipizide | Glipizide | 55 | 18 |
| Methylprednisolone | Methylprednisolone | 55 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 19 |
| Celecoxib | Celecoxib | 49 | 15 |
| Potassium Chloride | Potassium Chloride | 49 | 16 |
| Pregabalin | Pregabalin | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 16 |
| Prednisone | Prednisone | 43 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 41 |
| Lorazepam | Lorazepam | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 16 |
| Valsartan | Valsartan | 37 | 11 |
| Nifedipine Er | Nifedipine | 36 | 12 |
| Baclofen | Baclofen | 35 | 12 |
| Benazepril Hcl | Benazepril Hcl | 35 | 13 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | 12 |
| Colchicine | Colchicine | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 19 |
| Januvia | Sitagliptin Phosphate | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 14 |
| Ketoconazole | Ketoconazole | 24 | 12 |
| Oxazepam | Oxazepam | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.00 · 22 records | Lilly USA, LLC | ABRYSVO, CAPLYTA, COMIRNATY, FANAPT, GIVLAARI, INJECTAFER, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PYRUKYND, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Tlando, VOQUEZNA, VPRIV, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error